title: The role of interleukin-6 and of its soluble receptors in the biocompatibility of dialysis treatment.
abstract: Proinflammatory cytokines, in addition to their role in host defence, may be considered mediators of disease; a reduction of cytokine synthesis or effects is, therefore, becoming a target of many diseases. IL-6 is a pro-inflammatory cytokine that may play a role in several clinical problems related to dialysis treatment. An enhanced spontaneous production of IL-6 by Peripheral Blood Mononuclear Cells (PBMC) harvested from ESRD patients dialyzed with a poor biocompatible membrane has been first demonstrated by our group. These results were also obtained in patients undergoing continuous peritoneal dialysis, in absence of peritonitis. We have also demonstrated that IL-6 release was inversely correlated with serum albumin changes. Biological activities of IL-6 may be modulated by two soluble circulating receptors, namely sIL-6R and sgp130. sIL-6R may enhance the inflammatory effects of IL-6 and is, therefore, an "agonistically" acting molecule. We have recently studied sIL-6R production in ESRD patients dialyzed with different membranes; the conclusion was that poor biocompatible membranes, via the sIL-6R, might further increase the inflammatory effects of IL-6. On the contrary, sgp130 can efficiently bind the IL-6/sIL-6R complex with "antagonistic" effects. We have evaluated plasma levels of sgp130 in 18 ESRD patients regularly dialyzed with hemophan membranes (HE) and in 15 patients dialyzed with more biocompatible synthetic membranes (BIO). Our results demonstrate that plasma levels of sgp130 in HE are 33% higher than in both healthy controls and BIO. Circulating levels of sgp130 were correlated positively with C-reactive protein (r: 0.338, p<0.05) and negatively with serum albumin (r: -0.334, p<0.05). These results suggest that higher circulating levels of sgp130 are likely associated with higher IL-6 levels. These higher amounts are probably insufficient to control the activity of IL-6 and may be considered only as a marker of PBMC activation.
authors.affiliation: Department of Nephrology, University Frederico II of Naples, Naples, Italy.
authors.forename: Bruno
authors.initials: B
authors.lastname: Memoli
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Romano
authors.forename: Rosamunda
authors.initials: R
authors.lastname: D'arcangelo
authors.forename: Marco
authors.initials: M
authors.lastname: Del Prete
authors.forename: Pasquale
authors.initials: P
authors.lastname: Esposito
authors.forename: Alfredo
authors.initials: A
authors.lastname: Procino
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Cuomo
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Bisesti
authors.forename: Alfredo
authors.initials: A
authors.lastname: Capuano
authors.forename: Vittorio E
authors.initials: VE
authors.lastname: Andreucci
mesh_terms: D006801:Humans; D015850:Interleukin-6 / Q000502:physiology*; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000628:therapy; D019947:Receptors, Interleukin-6 / Q000502:physiology*; D006435:Renal Dialysis
chemical_list: D015850:Interleukin-6; D019947:Receptors, Interleukin-6